– ISRAEL / USA, CA – Medgenics, Inc. (NYSE MKT:MDGN and AIM:MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of Wilbur H. (Bill) Gantz to the Company’s Board of Directors effective October 16, 2013. With this appointment, the size of the Medgenics board increases to 10 directors.
Mr. Gantz is President of PathoCapital, an investor in healthcare companies. He previously served as Executive Chairman and Chief Executive Officer of Ovation Pharmaceuticals, Inc., which was sold to Lundbeck, AG in 2009, and as Chairman, Chief Executive Officer and President of PathoGenesis Corporation, a biopharmaceutical company that was sold to Chiron, Inc. in 2000. Prior to founding PathoGenesis, from 1987 to 1992 he served as President of Baxter International, Inc., a manufacturer and marketer of healthcare products. He joined Baxter in 1966 and held various management positions, including Vice President, Europe and President, International Division, prior to being named Executive Vice President and Chief Operating Officer in 1980.
“Bill is a prominent and highly regarded figure in the biopharmaceutical industry, and we are delighted to welcome him to our Board of Directors. He has demonstrated leadership at both global pharmaceutical companies as well as at a series of entrepreneurial biotechnology companies that he built and guided to success,” said Mike Cola, President and Chief Executive Officer of Medgenics. “Bill’s insights will be instrumental in guiding Medgenics as we advance our clinical development programs and build a successful biotechnology company.”
“I am delighted to be joining Medgenics at this important juncture in its clinical development,” said Mr. Gantz. “The Company’s novel, technology platform holds great potential to change the paradigm for therapeutic proteins across a number of chronic conditions. I look forward to working with the Medgenics team and my fellow directors to advance the development of this promising platform technology.”
Mr. Gantz is currently Executive Chairman, Naurex, Inc., a biotechnology company developing central nervous system therapeutics. He is a Vice Chairman of the Board of Trustees and Chair of the Committee on Science of the Field Museum of Natural History in Chicago. He is the former Chairman of the Board of Harris Financial Corporation and a former director of the Gillette Company, W.W. Grainger, Inc., Gambio, Inc. and Baxter International. He is a past trustee of Princeton University. Mr Gantz is 75 years old. In addition to the above, is a partner of Adam Street Partners, LLP and a director of Neurowave, Inc.
Mr. Gantz holds a BA degree from Princeton University, where he graduated cum laude, and an MBA from Harvard Business School.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others.
Related articles
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
